BridgeMD
New treatment option for COPD
Official title Closed Loop Oxygen Control in Chronic Obstructive Pulmonary Disease (COPD) Patients Treated With Nasal High Flow in the Hospital
ClinicalTrials.gov ID: NCT07222410
What this study is testing
- What it's testing
- The trial aims to evaluate whether the Airvo 3 device in OptiO2 mode can maintain patients' SpO2 levels within the target range better than manual oxygen titration in hospitalized COPD patients with hypoxemia/respiratory distress.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 22 and older
You may be able to join if
- Has cognitive ability to provide informed consent
- Aged 22 years or older
- Hospitalized with hypoxemia/respiratory distress
- Diagnosis of COPD
- Candidate for/currently prescribed nasal high flow (flow rate of at least 25 L/min) with supplemental oxygen, as assessed by the investigator
You likely can't join if
- Receiving Non Invasive Ventilation (NIV) or indicated for NIV as per European Respiratory Society /American Thoracic Society guidelines
- Hemodynamic instability (systolic blood pressure \<90mmHg or requirement for vasopressor or inotropic support)
- Patient receiving end of life care
- Nasal or facial conditions precluding use of nasal high flow
- Pregnancy or breastfeeding
- Cognitive impairment or impaired consciousness precluding informed consent
See the full eligibility criteria
- Has cognitive ability to provide informed consent
- Aged 22 years or older
- Hospitalized with hypoxemia/respiratory distress
- Diagnosis of COPD
- Candidate for/currently prescribed nasal high flow (flow rate of at least 25 L/min) with supplemental oxygen, as assessed by the investigator
- Expected duration of oxygen and nasal high flow therapy \>24 hours (not necessarily continuous)
- Receiving Non Invasive Ventilation (NIV) or indicated for NIV as per European Respiratory Society /American Thoracic Society guidelines
- Hemodynamic instability (systolic blood pressure \<90mmHg or requirement for vasopressor or inotropic support)
- Patient receiving end of life care
- Nasal or facial conditions precluding use of nasal high flow
- Pregnancy or breastfeeding
- Cognitive impairment or impaired consciousness precluding informed consent
- Unsuitable for adhesive finger pulse oximetry, as assessed by the investigator
- Any other condition which, at the investigator's discretion, is believed to present a safety risk to the patient if included
- The presence of any active comorbidities that affect the patient's condition importantly in the next 30 days, as assessed by the investigator
- Has already participated in this clinical trial
The study team makes the final eligibility decision.
Where it's taking place
- Birmingham, Alabama, United States
- Des Moines, Iowa, United States
- New York, New York, United States
- Philadelphia, Pennsylvania, United States
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 22 years and older. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Birmingham, Alabama, United States; Des Moines, Iowa, United States; New York, New York, United States; Philadelphia, Pennsylvania, United States. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.